Elena Zamagni MD, PHD, is Associate Professor of Hematology at the Bologna University, Italy. She received her medical degree from University of Bologna, where she also served her residency in haematology. She got PHD in Clinical Hematology at the University of Bologna in May 2005.

Her research interests include areas related to multiple myeloma, in particular on the role of high dose therapy with stem cell support, of prognostic factors, minimal residual disease and of imaging techniques.

She has published over 150 papers in peer-reviewed journals, mainly in the field of plasma cell dyscrasia. She has contributed to the educational session of the Italian Society of Haematology (SIE) and American Society of Clinical Oncology (ASCO). She is abstracts reviewer for SIE, EHA and ASH. She is part of the editorial board of several haematological journals, including Blood Cancer Journal and Journal of Clinical Oncology. She is an active member of the board of the GIMEMA and European Myeloma Network (EMN) working party and she has cooperated in the Scientific secretary and as principal investigator in several national randomized trials in multiple myeloma. She is a member of the Italian Society of Haematology, of the International Myeloma Working Group and of the International Myeloma Society. She is served on the EHA’s Scientific Program Committee from 2017 to 2021. She is part of the Scientific Program Committee for the European Society of Clinical Oncology since 2021. She is responsible for the career development committee within the International Myeloma Society since 2019 and member of the board of the IMS as European representative since 2023.